Adefovir dipivoxil
- Generic Name
- Adefovir dipivoxil
- Brand Names
- Hepsera
- Drug Type
- Small Molecule
- Chemical Formula
- C20H32N5O8P
- CAS Number
- 142340-99-6
- Unique Ingredient Identifier
- U6Q8Z01514
- Background
Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is ineffective against HIV-1. Adefovir dipivoxil is the diester prodrug of adefovir.
- Indication
Indicated for the treatment of chronic hepatitis B in adult patients with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease; this is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chroni...
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT00002379
- Locations
- 🇺🇸
Phoenix Body Positive, Phoenix, Arizona, United States
🇺🇸Saint Vincent's AIDS Ctr, New York, New York, United States
🇺🇸George Washington Med Ctr, Washington, District of Columbia, United States
Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT00002219
- Locations
- 🇺🇸
Bronx Lebanon Hosp Ctr / Dept of Pediatrics, Bronx, New York, United States
🇺🇸St Lukes Roosevelt Hosp Ctr, New York, New York, United States
🇺🇸Tulane Univ Med Ctr / Dept of Pediatrics, New Orleans, Louisiana, United States
The Safety and Effectiveness of Adefovir Dipivoxil in HIV-Infected Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Target Recruit Count
- 24
- Registration Number
- NCT00000843
- Locations
- 🇺🇸
UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States
🇺🇸Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States
🇺🇸Chicago Children's Memorial Hosp, Chicago, Illinois, United States
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 400
- Registration Number
- NCT00002161
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸East Bay AIDS Ctr, Berkeley, California, United States
🇺🇸Chicago Ctr for Clinical Research, Chicago, Illinois, United States
Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT00002398
- Locations
- 🇺🇸
Gilead Sciences Inc, Foster City, California, United States
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 15
- Registration Number
- NCT00002128
- Locations
- 🇺🇸
Johns Hopkins Univ, Baltimore, Maryland, United States
Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT00002220
- Locations
- 🇺🇸
Hawaii AIDS Clinical Trial Unit, Honolulu, Hawaii, United States
🇺🇸LAC / USC Med Ctr / Infectious Diseases, Los Angeles, California, United States
🇺🇸Med Ctr of Delaware, Wilmington, Delaware, United States
A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 390
- Registration Number
- NCT00002426
- Locations
- 🇺🇸
Health Positive, Safety Harbor, Florida, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸Thomas Street Clinic, Houston, Texas, United States
A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 300
- Registration Number
- NCT00000892
- Locations
- 🇺🇸
Cornell Univ Med Ctr, New York, New York, United States
🇺🇸Mount Sinai Med Ctr, New York, New York, United States
🇺🇸Univ of Tennessee / E Tennessee Comprehensive Hemophilia Ctr, Knoxville, Tennessee, United States
A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 475
- Registration Number
- NCT00000912
- Locations
- 🇺🇸
USC Univ Hosp & Ambulatory Hlth Care Ctr / USC Med Ctr, Los Angeles, California, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
🇺🇸UCLA CARE Ctr, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.